Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands		Total	Preferred Stock	Common Stock		Treasury Stock		Additional Paid-in Capital		Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance at Dec. 31, 2023		$ 62,471	$ 0	$ 1	[1]	$ 0		$ 361,898	[1]	$ (293)	$ (299,135)
Beginning balance (in shares) at Dec. 31, 2023			0	12,544,533	[1]	1,076,257	[1]
Shares issued during the period for vested restricted stock awards, shares	[1]			50,693
Stock-based compensation		1,639						1,639	[1]
Net loss		(8,771)									(8,771)
Other comprehensive gain (loss)		(181)								(181)
Ending balance at Mar. 31, 2024		55,158	$ 0	$ 1	[1]	$ 0		363,537	[1]	(474)	(307,906)
Ending balance (in shares) at Mar. 31, 2024			0	12,595,226	[1]	1,076,257	[1]
Beginning balance at Dec. 31, 2023		62,471	$ 0	$ 1	[1]	$ 0		361,898	[1]	(293)	(299,135)
Beginning balance (in shares) at Dec. 31, 2023			0	12,544,533	[1]	1,076,257	[1]
Exercise of warrants		0
Net loss		(21,012)
Ending balance at Jun. 30, 2024		44,241		$ 1	[1]	$ 0	[1]	364,825	[1]	(438)	(320,147)
Ending balance (in shares) at Jun. 30, 2024	[1]			12,700,258		1,076,257
Beginning balance at Mar. 31, 2024		55,158	$ 0	$ 1	[1]	$ 0		363,537	[1]	(474)	(307,906)
Beginning balance (in shares) at Mar. 31, 2024			0	12,595,226	[1]	1,076,257	[1]
Shares issued during the period for vested restricted stock awards, shares	[1]			100,908
Issuance of common stock upon exercise of stock options		3						3	[1]
Issuance of common stock upon exercise of stock options, shares	[1]			4,124
Stock-based compensation		1,285						1,285	[1]
Net loss		(12,241)									(12,241)
Other comprehensive gain (loss)		36								36
Ending balance at Jun. 30, 2024		44,241		$ 1	[1]	$ 0	[1]	364,825	[1]	(438)	(320,147)
Ending balance (in shares) at Jun. 30, 2024	[1]			12,700,258		1,076,257
Beginning balance at Dec. 31, 2024		19,036	$ 0	$ 1		$ 0		367,318		(542)	(347,741)
Beginning balance (in shares) at Dec. 31, 2024			0	12,853,823		1,076,257
Shares issued during the period for vested restricted stock awards, shares				209,486
Issuance of common stock upon exercise of stock options		3						3
Issuance of common stock upon exercise of stock options, shares				5,000
Stock-based compensation		280						280
Net loss		(3,819)									(3,819)
Other comprehensive gain (loss)		28								28
Ending balance at Mar. 31, 2025		15,528	$ 0	$ 1		$ 0		367,601		(514)	(351,560)
Ending balance (in shares) at Mar. 31, 2025			0	13,068,309		1,076,257
Beginning balance at Dec. 31, 2024		19,036	$ 0	$ 1		$ 0		367,318		(542)	(347,741)
Beginning balance (in shares) at Dec. 31, 2024			0	12,853,823		1,076,257
Exercise of warrants		7,927
Net loss		(19,249)
Ending balance at Jun. 30, 2025		9,042		$ 1		$ 0		376,464		(433)	(366,990)
Ending balance (in shares) at Jun. 30, 2025				14,872,017		1,076,257
Beginning balance at Mar. 31, 2025		15,528	$ 0	$ 1		$ 0		367,601		(514)	(351,560)
Beginning balance (in shares) at Mar. 31, 2025			0	13,068,309		1,076,257
Shares issued during the period for vested restricted stock awards, shares				53,708
Exercise of warrants, Shares				1,750,000
Exercise of warrants		7,927						7,927
Stock-based compensation		936						936
Net loss		(15,430)									(15,430)
Other comprehensive gain (loss)		81								81
Ending balance at Jun. 30, 2025		$ 9,042		$ 1		$ 0		$ 376,464		$ (433)	$ (366,990)
Ending balance (in shares) at Jun. 30, 2025				14,872,017		1,076,257

[1] * - Prior year shares and amounts, as applicable, have been revised to reflect the Reverse Stock Split effective November 29, 2024.